This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00372-07v1 51/9/3136    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanderson, L. Articles by Thomas, S. Search for Related Content PubMed PubMed Citation Articles by Sanderson, L. Articles by Thomas, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3136-3146, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00372-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Distribution of Suramin, an Antitrypanosomal Drug, across the Blood-Brain and Blood-Cerebrospinal Fluid Interfaces in Wild-Type and P-Glycoprotein Transporter-Deficient Mice

King's College London, Pharmaceutical Sciences Research Division, Guy's Campus, Hodgkin Building, London Bridge, London SE1 1UL, United Kingdom

Received 20 March 2007/ Returned for modification 22 May 2007/ Accepted 10 June 2007

Although 60 million people are exposed to human African trypanosomiasis, drug companies have not been interested in developing new drugs due to the lack of financial reward. No new drugs will be available for several years. A clearer understanding of the distribution of existing drugs into the brains of sleeping sickness patients is needed if we are to use the treatments that are available more safely and effectively. This proposal addresses this issue by using established animal models. Using in situ brain perfusion and isolated incubated choroid plexus techniques, we investigated the distribution of [³H]suramin into the central nervous systems (CNSs) of male BALB/c, FVB (wild-type), and P-glycoprotein-deficient (Mdr1a/Mdr1b-targeted mutation) mice. There was no difference in the [³H]suramin distributions between the three strains of mice. [³H]suramin had a distribution similar to that of the vascular marker, [¹⁴C]sucrose, into the regions of the brain parenchyma that have a blood-brain barrier. However, the association of [³H]suramin with the circumventricular organ samples, including the choroid plexus, was higher than that of [¹⁴C]sucrose. The association of [³H]suramin with the choroid plexus was also sensitive to phenylarsine oxide, an inhibitor of endocytosis. The distribution of [³H]suramin to the brain was not affected by the presence of other antitrypanosomal drugs or the P-glycoprotein efflux transporter. Overall, the results confirm that [³H]suramin would be unlikely to treat the second or CNS stage of sleeping sickness.

Published ahead of print on 18 June 2007.

This article has been cited by other articles:

• Mason, B. L., Pariante, C. M., Thomas, S. A. (2008). A Revised Role for P-Glycoprotein in the Brain Distribution of Dexamethasone, Cortisol, and Corticosterone in Wild-Type and ABCB1A/B-Deficient Mice. Endocrinology 149: 5244-5253 [Abstract] [Full Text]